Last Price
0.62
Today's Change
+0.01 (1.63%)
Day's Change
0.593 - 0.63
Trading Volume
58,486
Exchange: NASDAQ Capital Market NASDAQ Capital Market
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Mr. Peter H. Nielsen MBA Mr. Peter H. Nielsen MBA
Full Time Employees: 10 10
IPO Date: 2008-03-04 2008-03-04
CIK: 0001133818 0001133818
ISIN: US09057N3008 US09057N3008
CUSIP: 09057N300 09057N300
Beta: 0.22 0.22
Last Dividend: 0.00 0.00
Dcf Diff: -1.29 -1.29
Dcf: 1.96 1.96
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.